text:
1) Scope
A) These General Conditions of Sale (hereinafter the "Conditions") govern all the sale agreements for products and services (hereinafter the "Products") stipulated between SACE SRL A SOCIO UNICO, a company established and organised under the Laws of Italy, with registered office in Borgonuovo di Sasso Marconi (BO), Via Cartiera 154, (hereinafter "SACE") and the Purchasers (hereinafter the "Purchasers" or individually the "Purchaser"), subject to any other written agreements between the parties.
B) Any amendment or change to these Conditions shall not be applicable and valid for the Parties unless priorly approved in writing by SACE. SACE reserves the right to modify the content of these Conditions at any time and without prior notice.
C) In the event of discrepancies between these Conditions and any other special conditions expressly agreed in writing between SACE and the Purchaser, the latter special conditions shall prevail.
D) The Purchaser acknowledges and agrees that any contractual terms and/or general conditions prepared by the Purchaser shall not be applied in the contractual and commercial relations between SACE and the Purchaser, even in the event that such terms and conditions are mentioned and/or referred to in any document or communication exchanged between the parties.
2) Contract formation
A) No purchase order for the Products sent by the Purchaser shall be binding on SACE unless accepted by the latter in writing.
B) The Supply agreement shall be completed and come into effect as of the moment when SACE sends its written Order Confirmation.
C) Any change to the Supply agreement that may become necessary by mutual agreement of the parties, shall require issuing a new Order Confirmation by SACE, which shall be signed by the Purchaser for acceptance.
D) If the conditions required and provided in the Purchaser's order differ from those indicated in SACE's Order Confirmation, the latter shall be considered the new contractual version and the agreement shall be deemed accepted with the new conditions if the Purchaser does not express any objections within 5 (five) calendar days as of receiving the Order Confirmation.
E) The offers, if any, issued by SACE shall be valid only for the time period indicated and exclusively for the entire supply mentioned therein.
3) Technical data, drawings, documents connected with the supply
A) The data and illustrations provided in the catalogues, brochures, circular letters or other descriptive documents are purely indicative. Such data are not binding for SACE unless expressly mentioned as such in the Order Confirmation.
B) The Purchaser expressly agrees and undertakes not to use - for any purpose other than those envisaged in the supply agreement - the drawings, layouts, technical information and findings related to the supply, that shall remain the property of SACE and that the Purchaser may not deliver to third parties nor reproduce without SACE's prior written consent
C) SACE may modify the Products at any time, as deemed necessary and appropriate, notifying the Purchaser of any such changes.
4) Exclusion clause
A) Unless otherwise agreed in writing between the Parties, the supply shall not include the system design, the installation of the equipment supplied, specific tests, training courses and manuals, assistance during start-up as well as all the services, costs and products not mentioned in SACE's Order Confirmation.
B) Packaging costs, taxes, duty stamps, customs' charges and duties as well as any other additional cost are not included in the prices unless otherwise specified in SACE's Order Confirmation.
5) Prices and conditions of payment
A) The prices shall be those mentioned in SACE's Order Confirmation and in the offer, if still valid.
B) Unless otherwise agreed in writing between the Parties, all the prices are ex SACE's warehouse (EXW INCOTERMS).
C) Unless otherwise agreed, payments shall be made by the Purchaser within the deadlines envisaged and with the methods mentioned in SACE's Order Confirmation.
D) In the event of delayed payments, the Purchaser shall be bound to pay interests on arrears. These shall be calculated and rightfully applied without issuing a formal notice of default as provided for by Legislative Decree No. 231/2002 (enforcing Directive 2000/35/CE on combating late payments in commercial transactions) and shall be in addition to all banking expenses incurred. SACE shall always have the faculty to claim further and greater damages suffered and to terminate the agreement pursuant to Article 10 A) below.
E) The Purchaser shall be bound to pay the amounts due for the purchase made on the deadlines agreed. Before making any such payment, the Purchaser may not file, not even as an exception, any suits against SACE.
F) SACE shall handle orders and issue their Order Confirmation only if the value of the order commissioned exceeds the minimum amount required for order management, i.e. € 155.00 net.
G) SACE reserves the right, notifying the Purchaser one month before delivery, to change the price of the Products as a consequence of any increase in costs due to any reason outside SACE's control, there including, by way of example and not limited thereto: fluctuations in foreign exchange rates, currency regulations, change in customs' duties, major increases in the costs of materials, raw materials or labour or any other change in the suppliers' delivery terms.
6) Delivery terms
A) Unless otherwise agreed between the Parties, the delivery times shall be calculated as of the date of Order Confirmation, unless the Purchaser has to pay part of the price by way of advanced payment; in this case, the delivery term shall be calculated as of the date on which such payment was made.
B) The delivery terms shall be automatically and rightfully extended in the following cases:
1) if the Purchaser fails to provide the data or materials required for the supply, or if the Purchaser requests changes when the work is already in progress, or in the case of delayed responses to the requests for approval of the drawings or execution layouts;
2) if events that do not depend on SACE's goodwill and diligence, there including delays of sub-contractors, prevent any deliveries on the deadlines established or make such deliveries too onerous;
3) in the case of force majeure events, such as strikes, currency crises, earthquakes, fires, floods, wars, embargo, military mobilization, insurrections and any events that are not linked to SACE's will. In the aforementioned cases, SACE shall have the right to withdraw from the agreement without any obligation to refund damages.
C) In the event that the Purchaser has not regularly settled the payments pertaining to other supplies, the delivery terms shall be suspended and SACE may delay all deliveries until the Purchaser pays the amounts due. In the worst case, SACE may cancel the agreement in force in advance.
D) Should the Purchaser refuse to accept the delivery agreed when the goods are ready, the related amounts shall be paid as if the Products had been delivered.
E) Should the Purchaser not accept the delivery of the Products due to causes attributable to the same or, in any event, due to causes that do not depend on SACE's will, the Purchaser shall bear the risks and costs connected with their custody.
F) If the contractual relation is terminated, the Purchaser undertakes to unconditionally collect the goods in progress or on stock, in the quantities previously agreed with SACE, by and not later than 90 days following either the agreement termination, or a change in the technical parameters, or withdrawal from the agreement. After this deadline, SACE shall have the right to ship all the materials they have on stock, and to claim payment against the Products delivered.
7) Shipment, Packaging, Transfer of Risk, Solve et Repete
A) Unless otherwise agreed between the Parties, the Products shall be delivered ex SACE's warehouse (EXW INCOTERMS), also when the agreements provide that shipment shall be fully or partially managed by SACE.
B) Shipments made carriage forward shall always be at the risk and under the liability of the Purchaser; when this type of shipment is used, any claims for Product tampering or missing Products shall always be addressed directly by the Purchaser to the reference carrier or forwarding agent.
C) Immediately after receipt, the Purchaser shall check the goods and send a written claim in the event that discrepancies are found in the Product quantities received, within 5 (five) working days following the delivery date; if no claim is sent within five working days after delivery, the goods shall be deemed accepted for all legal effects and purposes.
D) If the Purchaser does not provide any instructions, we may not be held liable for the means of transport chosen nor for the rates applied by the carriers or forwarding agents. In the event that the agreement provides that the freight costs shall be borne, even only partially, by SACE, the means of transport shall be chosen by SACE only. Should the Purchaser wish to use a different means of transport, all the additional costs incurred shall be charged to the same.
E) Any transport insurance shall be subscribed only on request of the Purchaser, shall be made in the name of the Purchaser and shall be paid by the same.
F) Any claims or disputes shall not entitle the Purchaser to suspend or delay the payments due.
G) SACE shall pack the products based on their standard commercial practice. Special packaging or delivery instructions requested by the Purchaser shall be mutually agreed by the Parties and the related costs shall be separately invoiced to the Purchaser.
H) Unless otherwise agreed by the Parties in writing in the Offer or in the Order Confirmation, the risk for Product deterioration, damage or loss shall be transferred to the Purchaser "ex works" (INCOTERMS 2000), i.e. ex SACE's warehouse.
8) Retention of title
A) The Products within the scope of this Agreement are subject to "Retention of Title", therefore they shall remain the property of SACE until the price agreed has been paid in full.
B) The Purchaser shall be responsible for safeguarding the Products as soon as they are made available to them and shall be bound to keep the goods received at arm's length and agrees to allow SACE's personnel or persons entrusted by the same company to inspect such Products at any time, until the supply has been paid in full.
C) The Purchaser may not sell, donate, exchange, transfer, pledge, seize, alter or bind in any other manner the Products within the scope of this Agreement as long as their price has not been paid in full, unless SACE provides a written consent for this purpose.
D) In the event that preventative and/or executive measures are taken against the Purchaser using the goods received, the Purchaser agrees and undertakes to notify the bailiff that they are only depository of the goods and to inform SACE of this circumstance within 24 hours, by telefax, certified e-mail or registered letter with notice of receipt.
9) Warranty
A) To be entitled to the Warranty, and on penalty of warranty nullity, the Purchaser shall strictly observe the provisions given at the address: http://www.sace-srl.com/download/general-warranty-conditions/
B) The warranty for faults and defects of any nature and extent has a one-year term as of the delivery date of the goods and is exclusively limited to repairs or free replacement of the parts acknowledged to be non-conform due to material or manufacturing defects.
C) Product replacements or repairs shall be carried out ex SACE's works: the costs and risks for transporting the Products deemed defective shall be borne by the Purchaser. However, if SACE - in agreement with the Purchaser - deems that it is more appropriate to perform the replacement or repair works at the Purchaser's facilities, the latter shall bear the travel and lodging expenses, as well as the hourly labour cost (previously agreed) for the technical staff that SACE will make available. In addition, the Purchaser shall provide SACE with all the means and additional staff that may be required to perform the works as quickly and safely as possible.
D) SACE's warranty obligations shall become null and void in the following cases:
1) if the goods are returned without their identification labels;
2) if the Products were incorrectly assembled or improperly used, or if they were subject to poor maintenance or were modified without SACE's approval.
3) if the goods returned were disassembled or tampered with;
4) if the Products were hit or knocked;
5) if the electric parts were subject to voltage peaks or were wrongly connected.
E) In addition, SACE may not be held liable for Product conformity defects that are due to normal wear and tear of those parts that, because of their nature, are subject to fast and continuous wearing out.
F) In the event of proven non-conformity of the Component, any invoices from the Purchaser shall not be accepted. At SACE's sole discretion, if the Product found defective and therefore to repair or replace under warranty cannot be supplied, a credit note may be issued and wire transferred with a due date matching the supply terms.
G) Under no circumstance may a warranty claim entitle the Purchaser to cancel or decrease the quantity of Products ordered, nor to claim indemnifications or compensations of any nature.
H) The Purchaser agrees and undertakes not to use the Products purchased for any purpose other their intended use, and not to modify their construction or operation. Should the Purchaser fail to observe the aforementioned conditions, their right to the warranty shall become null and void.
10) Express termination clause
A) The Supply agreement shall be immediately and rightfully terminated pursuant to Article 1456 of the Italian Civil Code by means of a written declaration by SACE, whereby the company states that they want to apply this express termination clause in the event that the Purchaser:
1) fails to pay or delays payment of the amounts due;
2) delays collection or fails to collect the Products within the terms provided for under Article 6; 3) does not observe the confidentiality obligations provided for under Article 3 B). SACE will evaluate and claim consequential damages following the above resolutions.
B) The Agreement shall be terminated in the event that the Purchaser is in liquidation or is subject to any bankruptcy proceedings.
C) In the event that the Purchaser reduces the warranty provided on stipulation of the Agreement or does not provide the warranties envisaged, SACE shall have the faculty to withdraw from the Agreement without prior notice.
11) SACE's liability and disclaimer
A) SACE may be held liable only in relation to the proper operation of the Products, of the hydraulic and electronic systems and components supplied, based on the characteristics and performances expressly indicated in the Order Confirmation.
B) SACE may not be held liable for any defective operation of machines or systems manufactured or assembled by the Purchaser or by third parties using the Products supplied by SACE, even if the individual Products have been connected according to the layouts or drawings provided by SACE.
C) The Purchaser/manufacturer of the machine/vehicle in which the electronic controls with application software developed by SACE have been installed shall be held fully liable for all the consequences which may derive from the use of the machine/vehicle. Accordingly, SACE may not be held liable for any direct or indirect consequences caused by faults or malfunctions of the machine/vehicle. It is therefore the Purchaser's/manufacturer's responsibility to appropriately evaluate the risks and take all suitable measures to assure and safeguard the safety of personnel and of their facilities and equipment in the working place, pursuant to applicable legislation.
D) The Purchaser agrees and undertakes to hold SACE harmless from and against any claims/and or legal suits filed against SACE by the end user and/or by third parties in relation to alleged defects found in the machinery.
E) Furthermore, the Purchaser agrees and undertakes to hold SACE harmless from and against any claims/and or legal suits filed against SACE for the alleged violation of exclusivity rights as well as of industrial and intellectual property rights involving the machinery.
F) In any event, both on a contractual and extra-contractual basis and subject to the provisions of Art. 1229 of the Italian Civil Code, SACE's liability in relation to the Purchaser may not exceed half of the amount actually paid by the customer to SACE for performing the work or service entrusted.
12) Privacy
A) SACE and the Purchaser mutually acknowledge, in compliance with Art. 13 of Leg.Decree No. 196 dated 30/06/2003 (Privacy Law, on the Protection of Personal Data) that all personal information provided shall be handled exclusively within the scope of the agreement for the supply of goods and services and for the purpose of complying with applicable legislation. The information provided shall be processed in written form and/or on paper, IT, electronic or telecommunication means; in any event, it shall always be stored using proper and secure means. The data and information processed may not be disclosed to third parties, unless this is required to meet legal, accounting, administrative and other Law obligations. Providing personal data is mandatory as regards all legal and contractual requirements. Accordingly, refusing to provide such information in full or in part may prevent SACE from starting and executing all contractual relations. Pursuant to the aforementioned Law, the parties mutually acknowledge that the rights provided by Art. 7 of Legislative Decree No. 196 dated 30/06/2003 may be exercised at their own headquarters; in particular, they may exercise the right to access their own data, and to request additions to, updates and corrections of the information provided. The subject concerned may also request the deletion, blocking and modification in anonymous form of the data provided in the event of violations of the law.
B) The Purchaser shall hold SACE and their successors and assignees harmless from and against any damage claimed, burden or expense, be it direct or indirect, that the Purchaser or their successors and assignees may incur as a consequence of any failure to observe applicable legislation on the Protection of Personal Data.
13) Applicable law
A) All the supply agreements with foreign countries, governed by these General Conditions of Sale, shall be ruled by the Laws of Italy.
14) Place of jurisdiction
A) Any controversies related to the execution, interpretation, validity, resolution and termination of the Supply Agreements between the Parties shall be exclusively referred to the Court of Bologna.
Signature of the Purchaser:………………………………………….
After sending an own Supply Order and/or accepting SACE's order confirmation and consequent supply of the goods and services requested, the Purchaser confirms, approves and accepts all the clauses of these "General Conditions of Sale" and, pursuant to Art. 1341 and 1342 of the Italian Civil Code, declares to expressly approve the following clauses: 5) Prices and conditions of payment; 6) Delivery terms; 7) Shipment, Packaging, Transfer of Risk, Solve et Repete; 8) Retention of title; 9) Warranty; 10) Express termination clause; 11) SACE's liability and disclaimer; 12) Privacy; 13) Applicable law; 14) Place of jurisdiction.
Stamp and Signature of the Purchaser:……………….


text:
The Heart of the Battle
John Hurt (The War Doctor), Jacqueline Pearce (Cardinal Ollistra), Lucy Briggs-Owen (The Nursemaid), Carolyn Seymour (The Slave). Beth Chalmers (Veklin), Alex Wyndham (Seratrix), Kieran Hodgson (Bennus), Barnaby Edwards (Arverton), Mark McDonnell (Traanus) John Banks (Garv) and Nicholas Briggs as the Daleks.
Trapped in a citadel swarming with Daleks, the Time Lord rescue force must find a way to overcome insurmountable odds. With The Daleks apparently planning to rule the Null Zone, perhaps their thirst for universal conquest and victory has been quenched…
The War Doctor doesn't believe so – but how can he prove it without destroying any chance of peace?
As the countdown to the destruction of Keska proceeds, a deadly choice must be made… A choice that will define this Doctor, and perhaps forever cast him in the role of "monster".
In a flashback during the Taalyen invasion of Keska, Rejoice tries to argue her fatherout of going to negotiate with the Taalyens and Daleks.
In the present, Veklin and Bennus, are still navigating the service shafts of the command centre, when they hear The Daleks chanting "Peace in our time". Upstairs, Traanus confronts The Doctor and Seratrix (and Rejoice with them) and mocks them for trying to make peace with The Daleks. Seratrix succeeds in getting them out of the room, Veklin finds that The Doctor, Seratrix, and Rejoice are on the move. She begins to prepare demolitedition charges as well.
Seratrix, The Doctor and Rejoice meet in what used to be Thran's quarters, she gets emotional over her father's fate, but reins it in. Seratrix won't let The Doctor stop the drilling mechanism, there is about an hour until it reaches the planet's core. He is quite serious about trying to make peace with The Daleks, believing the Time War cannot be won. The Doctor is appalled by the plan, while Seratrix does make a compelling case, it's not a sound plan given what The Doctor knows and considering his past form with The Daleks. Meanwhile, Veklin and Bennus climb a service shaft to get to Seratrix's group.
In arguing their points, Seratrix points out that The Doctor was involved with the very beginning of the war, and fought The Daleks long before the war. Rejoice tells the story of how the Taalyens killed her father and his diplomatic team by flying their ship into the sun, and she castigates Seratrix for his plan.
Seratrix reveals that the Time Lords gave The Daleks the weapon that created the Null Zone, in response to The Doctor's use of the Time Destructor to destroy the Dalek time fleet. This was a gesture of good faith toward their peace intentions. Veklin breaks in with Bennus and tells Seratrix she is there to rescue him, but he doesn't want to be rescued. Seratrix insists Ollistra supports the plan, but that isn't what Veklin and company were told and the Doctor wonders why they've all been sent there.
However, they are interrupted by the explosion of Veklin's charges, which temporarily disrupt the Dalek sensors and communication. Bennus reveals that he is on Seratrix's side, as was Arverton, and pulls a gun on them. Seratrix admits he is going to turn them all over to the Daleks for the sake of the peace efforts and orders Bennus to shoot Rejoice to stop Veklin from extracting him, prompting Veklin to say she will kill Seratrix if he does. The Doctor intervenes in the flurry of threats, despite Rejoice's willingness to die to stop Seratrix. The Daleks send another squad to destroy the Time Lords.
Seratrix explains that the plan of the Daleks is to put hyperdrives in all the thousand worlds and move them to create a defended border around the null zone. The Doctor counters that The Daleks don't do defensive, they only attack because they irreversibly believe all life to be inferior to them and he suggests he can prove The Daleks are up to something worse. Seratrix gets Bennus to stand down, he and Veklin agrees to give The Doctorone chance. A Dalek break in and Bennus shoots it. They flee toward the old council chamber which is now the Dalek control centre, fighting Daleks and Taalyens along the way. Traanus gets a report about the Time Lords and goes to interfere.
Near the control centre, they manage to cut communications with the drill apparatus, which is approaching the core. The Doctor and company walk into the control centre and face The Daleks and Prime Dalek. The Doctor bluffs that the attacks weren't made by them but by other Time Lords, he says they are there as part of Seratrix's team to help restore communications with the drill. He calls himself John Smith and Seratrix is forced to play along. The Doctor and Veklin start to work and restore communications and the sensors. Unbeknownst to the Daleks, Veklin is also strategically placing demolitedition charges. With that done, Seratrix asks for clarificatedition of the Dalek plan. The Daleks call the plan as Seratrix said, but The Doctor elaborates that the surfaces of the planets will be destroyed in the process, The Daleks say the inhabitants will receive alternate living arrangements. Meanwhile, Traanus approaches the control centre.
The Doctor pulls up a schematic which shows that the real plan is to launch the thousand worlds at fifty times the speed of light at Gallifrey, utterly destroying it. Seratrix still tries despairingly to plead for peace but is exterminated by The Daleks. Before they can fire on the others, Veklin sets off the charges, which destroy the pathweb that lets The Daleks communicate, the relevant overload deafens and overwhelms The Daleks, knocking them out. The Doctor says this allows the Keskans to retake their world and destroy The Daleks, however that will still leave the Taalyens to deal with.
The Doctor re-establishes communication with the drill again, and contacts Garv, who, along with others, is aboard the drill. Traanus breaks in and confronts them, willing to kill them even at the cost of his life, but when Rejoice points out The Daleks' real plan, he rethinks his willingness to sacrifice all the Taalyens. He lets The Doctor proceed communedition with the drill crew.
Garv knows the only way to stop the drill is to blow it up before it reaches the core. It will cause surface disruptions, but most of the populationwill survive. However, it requires a signal from the control centre to release control to the on-board crew. The Doctor wants to save Garv and his crew but he knows he can't. Traanus mocks him for his indecision but The Doctor states that he's known he is a monster already and only a monster would make this decision. Rejoice, affectionately, offers to do it in his place and take the guilt, but The Doctor refuses and presses the button, relinquishing control to the drill. Garv says his grateful goodbyes to The Doctor and then blows up the drill.
The Doctor comments on Seratrix's plan, and admits it was hopeful, but misguided. Traanus mocks him again and tries to kill The Doctor with a knife. Rejoice tackles him and takes the blow instead. Incensed, The Doctororders Veklin and Bennus to hold Traanus so that he can stab him in retribution, inciting more mockery, Veklin stops him. As The Doctor's rage fades, Traanus suggests The Doctor's punishment for his weakness is to live. However, it's short-lived, as a Battle TARDIS, piloted by Ollistra, appears around them, whisking them away.
Ollistra dismisses Veklin, who is outraged that she doesn't understand how this was done, TARDISes shouldn't be able to operate in the Null Zone. She orders Veklin to forget everything, on pain of dematerialisation. The Time Lords are currently wiping out the relatively-underpowered Daleks and their Taalyen allies. Without time travel technology, The Daleks are disadvantaged, Ollistra agrees it is a massacre, but not of the innocent.
Ollistra explains to The Doctor that she engineered all this because she couldn't risk allowing Seratrix's plans for peace to contaminate the rest of the population. So she gave Seratrix the null zone weapon with a backdoor built in and sent him undercover for this purpose, so that he would ultimately be removed. Bennus and Arverton were his agents, but when The Doctor prevented their deaths at Omega One, she was forced to think The Doctor may be as well. Therefore she arranged this mission to get rid of them all, now, she has shut down the Null Zone weapon and the Time Lords are cleaning up the operation. Seratrix will be a martyr and the Doctor's real loyalties were proven, Veklin, loyal to Ollistra, would have been unfortunate collateral damage. Despondent, The Doctor considers Ollistra bloodthirsty, her plan, though successful, still wove death and destruction over a thousand worlds.
Ollistra takes him to a beautiful pastoral world, informing him that it is Keska in the future. The planet has healed and the memory of the war is now mostly forgotten. A memorial to Rejoice stands and she is considered a symbol of peace and hope among the Keskan people. Ollistra doesn't know if she survived her stabbing, though. Still, she chides The Doctor for thinking himself sympathetic and forgetting that he, like all Time Lords, is a warrior.
His TARDIS buried where they stand, The Doctor summons it to the surface with his sonic screwdriver. He tells Ollistra goodbye and says he hopes he never sets eyes on her again. Still, she is glad he is on their side and will fight to the end. He admits it but says he doesn't feel the need to enjoy it. She wants to know where she can find him, should she require him again. In response, he says"at the heart of the battle, where the blood of the innocents flow, and only the monstrous survive…"
The Heart of the Battle was the third and final audio story in the anthology Only the Monstrous, produced by Big Finish Productions. It was written by Nicholas Briggs and featured John Hurt as the War Doctor and Jacqueline Pearce as Cardinal Ollistra.
This story follows on directly from the events of the Thousand Worlds.
Seratrix wonders if The Doctor wanted to survive the activation of the Time Destructor. (The Innocent)
Seratrix blames The Doctor for the start of the Time War. (Genesis of the Daleks)
The device to create the null zone was taken from the Omega Arsenal. (The Day of the Doctor)
The Daleks intend to collide several planets into Gallifrey. (The Apocalypse Element)
The Doctor calls himself a monster again. (The Innocent)
Seatrix asks The Doctor if he is a monsteror a coward. (The Parting of the Ways)
Rejoice questions if The Doctor is a good man. (Deep Breath)
The Doctor exploits the Dalek pathweb. (Asylum of the Daleks)
Bennus mentions the sky trenches (The Last Day) and the transduction barrier. (The Invasion of Time)
The Daleks' plan is similar to the one that they employed after their invasion of Earth in the 22nd century. (The Dalek Invasion of Earth)
coming soon

subset: commoncrawl


text:
Jersey City Catholic school with famed basketball program fights to stay open
NEW JERSEY (FOX 5 NEWS) - The name Bob Hurley Sr. is synonymous with St. Anthony High School. The longtime basketball coach has been a spokesperson for the Jersey City school, and now his voice is as important as ever.
St. Anthony is known for its national powerhouse basketball program. Over his last 49 seasons, Hurley has won 28 state championships and sent more than 150 players to Division 1 programs.
Since 1992, the school has had a 100 percent graduation rate. The valedictorian has been on the team each of the last two seasons. So that long success both on and off the court is a perfect backdrop for the larger story. This could be the end. The inner-city school has struggled with fundraising for years, and the deficit has caught up.
The small Catholic school is set to close its doors for good at the end of the 2017 school year unless it can raise about $600,000 by June 30.
In midst of this daunting reality, Hurley is ever the optimist. He has three fundraisers planned over the next few months, with the hope that even those without St. Anthony ties will pitch in to save not just this program, but a school that he says changes lives.


text:
BuddyGuard Intelligent Home Security System
By NinjaSpy
In Home Security
May 13th
0 Comments
4593 Views
Meet the BuddyGuard Flare: an intelligent home security system that respects your privacy and helps you monitor your home. It has a HD camera, motion detector, speaker, siren, accelerometer, microphone, temperature sensor, and WiFi/3G modules. It relies on AI to recognize your face or voice. Flare knows when you have left your home and activates automatically.
The BuddyGuard Flare is easy to install and relies on encryption to protect your data. It is pet friendly, so you don't get constant notifications when they play. You can use your face, voice or the location of your smartphone to control Flare. Like what you see? The Flare is available on Kickstarter at this time.[where to get it]
*Disclaimer: Our articles may contain aff links (#ads). As an Amazon Associate we earn from qualifying purchases. Please read our disclaimer on how we fund this site.
People who visited this gadget also visited:


text:
Advances in Lung Cancer Diagnosis May Hold Key to Fighting the Disease
Posted on January 8, 2015
(BPT) – For years, doctors treated lung cancer as one disease. The discovery of molecular biomarkers and advent of biomarker-driven therapies, however, has led to the understanding that lung cancer is actually made up of many distinct subtypes, which impacts the way the disease is diagnosed and treated. Testing a lung cancer tumor for molecular […]Read More


text:
Outplayed by Lila Rose Cover Reveal
I am a huge Lila Rose fan and I can tell you that every single one of her books are so good. Today, though I have a cover reveal for a book that I happen to have already read and the review is coming soon. It's the story everyone has been waiting for! Oh plus there is a giveaway!
Title: Outplayed
Author: Lila Rose
Genre: Contemporary Romance
Cover Design: Romantic Book Affairs Designs
Photo: Wander Aguiar
Release Date: May 21, 2019
Violet Marcus's life is settled. She has it all: a place of her own, a business where her temper has its uses, and great people who work for her.
But something is missing. The problem is, her stubbornness refuses to admit how lonely she actually is.
She lost the one man she thought she could marry, a university love, but when their careers drive them in different directions they went their separate ways.
Now he's back.
He's also changed.
Unsure if she wants to hug him or throat punch him, she keeps her distance. Or tries to.
Travis Stewart moves to Ballarat for one reason—to have Violet back in his life. His love has never diminished. Not through the years, the distance, or even in the underworld he finds himself a part of.
He will always love her.
Now he just has to convince Violet that his heart is hers, and his soul isn't as black as it seems.
His mission is simple: get Violet to understand they have a future together before getting kneed in the balls. Easy, especially as he refuses to be outplayed.
PRE-ORDER LINKS – 99c for a limited time only!!
US: https://amzn.to/2V1JIvX
UK: https://amzn.to/2UNJTWH
CA: https://amzn.to/2GGtsGG
AU: https://amzn.to/2IQF9hm
B&N: http://bit.ly/2ZBINAQ
Kobo: http://bit.ly/2GGaXn4
Apple Books: https://apple.co/2W5Aifq
Lila was born in Brisbane Australia, her step-dad was in the Army which caused them to move around a lot. They finally settled in country Victoria, Australia. Being the youngest of four children she admits she was spoilt a bit. Even drove her mum crazy when she refused to eat meat at a young age.
Now, Lila lives with her husband and two children.
She started writing in 2013 and self-published the first of the Hawks MC: Ballarat Charter series- Holding Out. Since then, she has published eleven other titles, which range from erotica, humorous romance, YA and paranormal.
Email: firstname.lastname@example.com
Website: https://www.lilarosebooks.com
Facebook: https://bit.ly/2AD9wES
Twitter: https://twitter.com/LilaRose78
Instagram: https://www.instagram.com/lilarose78
Enter to Win a $10 Amazon gift card + a travel mug (2 winners, open internationally)a Rafflecopter giveaway
Disclosure: This post contains affiliate links, especially Amazon. This means I may earn a commission should you chose to purchase a book or product using my link.
2 Comments
Debbie P
This book sounds like a fantastic read.
Great book & cover. Thanks for sharing.


text:
Why The FDA's Approval Of A New Alzheimer's Drug Should Worry You
You might expect Mariah Robertson to applaud last week's approval of a new drug for Alzheimer's disease. The 38-year-old Johns Hopkins University physician has seen the toll it takes on her patients, as well as on her own mother, Nancy Dreisinger, who was diagnosed with it at age 57.
Dreisinger, who was a senior officer at the local bank, started forgetting the details of projects and showing up late to meetings, straining relationships with co-workers and friends. Later, she lost motor skills and the ability to perform daily tasks ― which was especially painful to watch, Robertson told HuffPost, because her mom took such pride in her self-reliance. "She was so dynamic and so brilliant and so hardworking."
Once Dreisinger required round-the-clock care, Robertson, then in her 20s, helped provide it while juggling graduate studies in public health. By the time Dreisinger died in 2012, Robertson had enrolled in medical school in order to become a doctor.
"I wanted to understand the medical side of it," she said, and "change the way we care for people who are experiencing dementia, and also their caregivers and their families."
Aduhelm, the new Biogen drug that got clearance from the U.S. Food and Drug Administration (FDA) last week, is supposed to offer that kind of change. It's the first federally approved drug that seeks to slow the underlying biological process of Alzheimer's rather than simply mitigate symptoms.
Nobody thinks it's a cure, but advocates say it can stall disease progression and maybe be the first in a series of new treatments that will turn Alzheimer's into a manageable chronic condition.
Robertson takes a very different view. She says the scientific evidence comes nowhere close to justifying the claims on the drug's behalf, let alone the $56,000 Biogen plans to charge for a year's worth of treatment.
She is thinking about her patients, she said, but also about herself, because the kind of early-onset Alzheimer's that Dreisinger suffered is thought to have a genetic component.
"I would be lying if I said I didn't always think about the potential that I will acquire dementia someday," said Robertson. "I want this to be the treatment. I want this to work. I want the medicine that might help slow down my progression of dementia in the future. I want it for my patients who are suffering so much. … But this isn't it."
Robertson's sentiments are not unusual. Scientists across the country have expressed dismay over the FDA's decision and the process that led to it, including the agency's willingness to ignore the advice of an outside advisory committee that voted almost unanimously against approval. Three members of that committee have since resigned in protest, with one, Harvard Medical School Professor Aaron Kesselheim, calling the FDA decision "probably the worst drug approval … in recent U.S. history."
Aduhelm is not the first drug to generate such controversy. But it may prove to be the most financially consequential, given the price and number of Americans who could end up taking it. That, in turn, could reshape ongoing political debates over whether to reform the FDA itself and whether to enact legislation that would force down the price of prescription drugs.
The common thread linking those debates is a long-running argument over whether giving the government more sway over the pharmaceutical industry will dampen innovation. The answer, according to a variety of political conservatives and industry advocates, is yes ― that holding drug approvals to higher standards or restricting manufacturers' ability to set prices will lead to fewer medical breakthroughs.
If Aduhelm's critics are correct, its story may end up demonstrating why that argument is flawed. The FDA's decision could actually steer future research in less productive directions, prolonging the wait for a successful treatment, while simultaneously making it harder to fund programs that Alzheimer's patients and their families need.
In short, it could mean more suffering rather than less.
A Sticky Problem
Aduhelm seeks to slow the progress of Alzheimer's by attacking so-called amyloid proteins that accumulate in patients' brains. These "sticky" proteins have been an object of scientific inquiry ever since the early 1900s, when the German psychiatrist Alois Alzheimer first saw them in the autopsy of a woman he had been treating after she developed dementia while still in her 50s.
More than a hundred years later, exactly what role amyloid proteins play in Alzheimer's remains unclear. One theory is that, as they form clumps or "plaques," they somehow prevent the transmission of chemical signals among cells, interfering with the thinking and memory processes. It's also possible amyloid plaques damage the brain by causing inflammation or by hindering blood flow that supplies oxygen.
The hope has been that reducing or preventing the plaques can stall the disease. And "hope" is the right word. Pharmaceutical companies have now tried this with more than a dozen drugs, refining the approach with each successive attempt. Each one failed to produce clear, significant improvement.
I want this to be the treatment. I want this to work. I want the medicine that might help slow down my progression of dementia in the future. … But this isn't it.
Mariah Robertson, assistant professor of medicine at Johns Hopkins University
Interim results from a pair of large Aduhelm trials suggested it was no different. Although the drug was clearing out amyloid plaques, it wasn't producing significant clinical benefits, and Biogen ended the studies. But when company researchers went back over the data, including three months of late results that weren't part of earlier analyses, they found better outcomes in a group within one of the two trials.
"Better" is a relative term. Patients in that group, all of whom had gotten the highest doses of medication, were still losing cognitive and intellectual abilities. They just weren't losing them as quickly as those who had gotten the placebo. And the difference was less than what researchers or the FDA would typically consider clinically meaningful.
On top of that, the difference hadn't shown up in the parallel study. Biogen researchers argued that with more analysis and culling of data, it was possible to see signs of the positive effects in that other trial, too. But that kind of after-the-fact reasoning made many outside experts even more skeptical.
Among them were members of that FDA outside advisory panel, including University of Washington biostatistician Scott Emerson. At a public hearing about the drug, he likened the company's argument to "someone first firing a shotgun at a barn and then painting a target around the bullet holes."
In the end, 10 of 11 members sitting on the FDA's outside advisory committee recommended against approval, with the eleventh abstaining.
The FDA's Great Departure
The FDA's decision to ignore that outside recommendation was unusual. It does that only about one-fifth of the time, and almost never in the face of such an overwhelming vote against approval.
It also happened in an unusual way. To justify its decision, the FDA recognized the weak evidence of clinical benefits and cited, instead, Aduhelm's ability to reduce amyloid plaques. In making that judgment, the agency was relying on its authority to offer "accelerated approval" for treatments when a drug's proven biological effect "is reasonably likely to predict clinical benefit."
The original impetus for giving the agency that power was the experience with early HIV treatments, which were understood to reduce viral load before they were shown to deter the opportunistic infections associated with AIDS. Since then, the FDA has used the authority frequently to approve cancer drugs based primarily on their ability to reduce tumor size.
But many of those drugs have since proven ineffective at changing outcomes. Scientists working on Alzheimer's think the same thing could happen with Aduhelm ― in part because scientists aren't sure that getting rid of the plaques will really alter the disease's course.
Among the reasons for doubt, according to Donovan Maust, a University of Michigan geriatric psychiatrist who treats Alzheimer's patients, is that scientists still aren't sure reducing plaques will actually affect the deterioration of mental skills.
"In studies where people get regular cognitive testing and then you look at the brains at autopsy, the amount of sticky protein does not closely correlate with their cognitive performance," Maust said.
You're talking 24-hour care and a much heavier burden on the family. … Can you push that back three, six months, a year? That's precious time.
Maria Carrillo, chief science officer at the Alzheimer's Association
The FDA's willingness to endorse Aduhelm anyway has some critics wondering about the agency's reliability, especially because FDA scientists worked closely with Biogen throughout the process. The watchdog group Public Citizen has called for an investigation, blasting what it called an "inappropriate close collaboration with Biogen."
At the public hearing over the drug's application, the FDA official in charge of the neuroscience division "was overwhelmingly positive in a way that we've never simply never seen before," according to one biotech analyst who watched the proceedings and was quoted in the trade publication Endpoints.
Cooperation between industry and the agencies regulating them is common nowadays. It's supposed to make the approval process less cumbersome and inscrutable. But many experts have long called for measures to put more distance between the FDA and drug manufacturers, precisely because they worry it makes the agency too eager to approve questionable drugs.
In the meantime, the Aduhelm decision could set a precedent for how the FDA approaches other treatments ― an "enormously risky move," as STAT writer Matthew Herper put it, "that could accelerate the public's access to medicines but upend the future of drug regulation, forcing the 114-year-old agency to do the equivalent of redesigning a fighter plane in mid-flight."
The Patients And Their Advocates
Aduhelm has some strong advocates, too. None may be as visible or influential as the Alzheimer's Association, a massive organization that provides direct assistance to families and lobbies Congress to spend more on research and support.
Maria Carrillo, the association's chief science officer, laid out the case for the drug in an interview with HuffPost. She suggested it could draw yet more money into drug development. She also talked about the significance of a seemingly small improvement in symptoms or a short delay in their onset.
"I remember when my mother-in-law had early dementia, before she transferred into moderate, and what that meant for our family," Carrillo said, relating her own firsthand experience just as Robertson had. "Once you get into moderate, you're talking 24-hour care and a much heavier burden on the family. … Can you push that back three, six months, a year? That's precious time."
A big focus for the association has been showcasing patients' perspectives, which it says critical scientists like those on the FDA's advisory committee don't always appreciate.
Among its more visible efforts was a public relations campaign this year touting the value of "more time" that included tweets from celebrities like the actor Samuel L. Jackson. And in response to independent assessment questioning Aduhelm's value, the association wrote in a public letter that it could "add weeks, months, or even years of active life for those affected every day by the crushing realities of Alzheimer's."
But those kinds of statements alarm critical experts like Jason Karlawish, a University of Pennsylvania professor of psychiatry and author of a new book, "The Problem of Alzheimer's."
"The results of studies of aducanumab don't allow reasonable conclusions about the count of days of active life a person living with Alzheimer's disease will receive from taking the drug," he said.
Maust, the University of Michigan professor, had a similar reaction when he heard the association's claim: "It … unrealistically inflates expectations of people who are desperate ― potentially increasing demand for the treatment, but then also setting people up to be incredibly disappointed when these unrealistic expectations are inevitably not met."
The FDA has now lowered the bar for what it takes to put a drug into practice. That's not a good thing for my patients.
Jason Karlawish, author of "The Problem of Alzheimer's"
Other experts are more supportive ― among them, health economists Dana Goldman and Darius Lakdawalla from the Schaeffer Center for Health Policy and Economics at the University of Southern California, who wrote in an op-ed for STAT that "every week symptoms are delayed is a psychic and financial blessing."
But, as they noted, they have both served as consultants to Biogen, potentially giving them a financial incentive to tout the drug.
Possible financial interest in the drug's success has also become an issue for the Alzheimer's Association. Like many disease advocacy groups, it receives support from the drug industry, including from Biogen.
Harry Johns, the association's president and CEO, said in response to questions about these donations, "No contribution from any company, entity or individual impacts Alzheimer's Association decision-making, nor our positions on issues related to people living with Alzheimer's, other dementia and their families. We act solely based on the science and the needs of our constituents."
The Mind-Boggling Costs
Even a small chance of mild improvement might seem like reason enough to approve a drug for a disease as awful as Alzheimer's. But like all medications, Aduhelm has potentially dangerous side effects, including brain swelling. Doctors administering the drug during the trials watched for that aggressively using brain scans. One concern is that clinicians outside of academic settings will be less attentive.
And then there is the drug's financial cost. Rather than approving the drug strictly for people in earlier phases of the disease, which is what Biogen studied and when scientific theory would predict it has the best chance of impact, the FDA approved it for all Alzheimer's patients. That's nearly 6 million people, most of them elderly and on Medicare.
It makes the financial impact of Aduhelm approval mind-boggling, even if you're the type of person who has followed these debates for years and long ago became jaded about high drug prices. Annual Medicare spending on the treatment could top $100 billion, dwarfing the $39 billion it now spends on all similarly infused drugs.
Aduhelm will also strain state governments because the Medicaid programs they run will pick up part of the costs through coverage of low-income Alzheimer's patients, including seniors on Medicare who use Medicaid as a supplement. Unlike the federal government, states cannot deficit spend, so even a modest responsibility for such an expensive drug could cause financial problems.
And the part of the Aduhelm bill that doesn't put a claim on federal or state treasuries will impose costs on private insurers and consumers in the form of higher premiums or out-of-pocket costs.
The dollars that governments and individuals spend on Aduhelm are dollars they won't be able to spend elsewhere. And that's another reason so many experts and clinicians are angry about the approval.
As it is, patients and families struggle to pay for the support that people with Alzheimer's need ― starting with the cost of direct caregivers, whether in homes or in group settings. The inability to pay for these things cascades through the system, resulting in underpaid caregivers and understaffed facilities, all of which lead to more patient suffering.
Biogen, whose stock soared on the announcement of FDA approval, said in a statement to HuffPost that "we believe the price of Aduhelm is substantiated by the value it is expected to bring to patients, caregivers, and society." It also reiterated its pledge to work collaboratively with government agencies to alleviate the drug's financial strain on both individuals and society as a whole.
The likely result will be a combination of discounts and special charity programs, similar to the programs that drug companies run for high-priced drugs to treat cancer and other ailments. But typically, those efforts do more to shift spending than to reduce it. And they don't cover associated costs like brain scans to check for swelling.
As Rachel Sachs, a law professor at Washington University in St. Louis and top expert on drug pricing, wrote this week in the journal Health Affairs, "the potential financial implications for our health care system are staggering."
The Debate In Washington
In other developed countries, governments decide whether a drug is safe and effective ― and, then, how much the drug should cost. In some places, like France, Taiwan and the U.K., independent agencies make recommendations about price based on a variety of factors, like how new therapies compare to existing ones and just how much benefit they actually provide.
The closest thing to that in the U.S. is an independent nonprofit organization called the Institute for Clinical Effectiveness Research, which conducts such analyses on its own. When ICER looked at Aduhlem, it concluded that a year's worth of therapy should cost no more than $8,300 per patient ― in other words, one-seventh of what Biogen plans to charge.
The federal government can't do anything about that, because, unlike its foreign counterparts, it has no mechanism for direct negotiation of prices. Changing that has been a cause of reformers going back to the 1990s. But it has mostly been a campaign of futility, thanks in part to advocacy and lobbying from the pharmaceutical industry, which is among Washington's most powerful groups.
President Joe Biden and Democratic leaders in both houses have said they want to enact some kind of legislation giving the government more power, perhaps based on a 2019 bill that House Democrats passed. But it's not clear whether House Democrats can pass a new version of the same bill now, because their majority is much smaller. Getting votes in the Senate promises to be even harder, given that Democrats have just 50 votes, the bare minimum it would take to pass legislation.
The news about Aduhelm could push the cause forward. Among those attacking Biogen's proposed price as "unconscionable" was Sen. Ron Wyden (D-Ore.), chairman of the Senate Finance Committee. Similar dynamics have played out before, most memorably, when a surprise premium hike from a California health insurer helped Democratic leaders really support that they needed to pass the Affordable Care Act in 2010.
But Aduhelm is set to hit the market within a month ― long before legislation can pass, let alone take effect. For now, the federal government's most effective tool to control what Medicare spends may be to issue what's known as a "national coverage determination," limiting the circumstances in which it paid for the treatment. That could mean, for example, covering the drug only for patients in the early stages of the disease.
The agency that runs Medicare has made such decisions before, though rarely for pharmaceutical products. It would surely disappoint many patients and families who are now hoping for the drug and just as surely create a political backlash, with Republicans accusing the Biden administration of rationing life-altering treatment in a preview of how they imagine a government takeover destroying American health care.
The Real Effect On Research
Behind the cartoonish "death panel" version of that argument is a more serious claim that more FDA scrutiny or more government leverage over prices will discourage drug companies from making the inherently risky research investments that breakthroughs require.
The precise relationship between drug company profits and innovation is a subject advocates and experts have been arguing over for decades, and about which reasonable people can disagree. But critics of the Aduhelm decision worry that drug companies now have less reason to sweat out whether experimental Alzheimer's products show meaningful clinical progress.
"You're going to have all sorts of companies asking to be treated the same way as Biogen, under the same rules and using the same surrogate, bringing ever more expensive therapies to market," said Joseph Ross, a Yale professor of medicine and public health who specializes in the drug regulatory process. "You're going to get a whole bunch of ineffective, 'me too' drugs that aren't going to improve the lives of our patients."
Karlawish agrees. "The FDA has now lowered the bar for what it takes to put a drug into practice. That's not a good thing for my patients, their families, and added up across the millions who have the disease, that's not a good thing for society."
You're going to get a whole bunch of ineffective, 'me too' drugs that aren't going to improve the lives of our patients.
Joseph Ross, Yale professor of medicine and public health
As an example, Karlawish pointed to another Alzheimer's drug in development, this one from Eli Lilly, that had some promising early results but whose ultimate clinical effects remain unknown. "It's very interesting data … I cannot wait to see what more trials show. But given what the FDA just did, an awful rhetorical question looms: Why not just approve it tomorrow?"
Going forward, the best-case scenario is probably that reducing amyloid plaques has the effect that Aduhelm proponents hope ― and that, with improvements, such treatments can stop disease progression by acting on their own or (more likely) in combination with other therapies, much as the HIV "cocktail" of multiple drugs now works.
But many scientists worry that the intense focus on amyloid protein has distracted researchers from other theories of the disease that need more study. With the FDA's decision, drug companies now have less financial incentive to pursue those approaches.
One way to help settle those ongoing arguments on the drug's effectiveness would be to get a fuller understanding of it ― which, in theory, Biogen is now going to do. A condition of the FDA's approval was that the company conduct another randomized and controlled trial to establish more clearly whether the improvement from the one subgroup was real. This is a standard requirement for accelerated approvals.
But shortly after FDA announced approval, Biogen's CEO said he thought the follow-up trials could take nine years to complete. And even that might be wishful thinking. Drugmakers frequently fail to meet requirements for confirmatory experiments ― in part because recruiting people for studies gets a lot harder when a drug is available.
"The sad thing is that one more study of aducanumab could have told us answers to the question [over the precise role of amyloid] because clinical studies are one of the best ways to validate causal mechanisms," Karlawish said. "Together, FDA and Biogen blew it."
Robertson agrees and said she isn't looking forward to the conversations that await. Biogen has said Aduhelm will soon be available in 900 facilities around the country. This week, she starts a new position as an assistant professor at Johns Hopkins and knows that patients will be asking for the drug.
She plans to tell them what she thinks about it, even though she doesn't relish deflating their hopes ― and even though she believes science really will find a way to fight Alzheimer's. She just doesn't think it's happened yet.
CORRECTION: An earlier version of this story misidentified Dana Goldman and Darius Lakdawalla as clinicians.
Calling all HuffPost superfans!
Sign up for membership to become a founding member and help shape HuffPost's next chapter


text:
Visit the GD28 small shop!!!
Other websites
www.syeir.dk : Peter Haagen onboard Eir tells about his one year long trip to Brasil (South America, yes!) and back - there's some nice photo's too. He has reached the Acores Islands on his way back after a 36 days trip across the Atlantic in August 2007 and after Kinsale in Ireland (beginning of October) and Oban in Scotland, he's back in Denmark via the Caledonian Canal (December 07). In Danish.
www.selfsteer.dk : Aries windvane. In 1988, Peter Matthiesen borrowed his father's GD28 for what was supposed to be a summer trip and ended up in New Zealand more than 2 years after!
A sailor dictionary: Aphrodite 101 boat website hold the best dictionary seen with nautical words in danish/swedish/english/french/spanish/german…. But to find words such as water, wind, food, beer or sing press the following link…
english-danish dictionary : Goes in both direction. Not for particular 'sailors' vocabulary, but still pretty complete and useful.
This website was originally created to replace the one opened by Dave Bunn which was supposed to be closed down for financial and time reasons. As it's still there, go and have a look, you'll find pictures and some good stories.
- In english 'The Long Voyage Home' by R. Lancy Burn, ed. Arseya LLC, 2004: How he crossed the Atlantic aboard his GD28 'Blue Gipsy' after buying her in Denmark and going to South Carolina in 1971 (his first crossing).
- In english: Great Dane 28 are cited in two books we know of; the first one is Seraffyn's European Adventure by Lin Pardey when then sailed in North Europe during th 70's (they give a description of the boat) and the second one is Singlehanded Sailing: The Experiences and Techniques of the Lone Voyagers by Richard Henderson first written 1976 (a GD28 owner says he prefer hulling to instead of heaving to in rough weather).
Boat magazine articles
- Practical Boat Owner, April 2004, p 128-131, Great Dane 28 - The greatest Dane of all? by David Harding (in english)
- Yacht, Heft 10/1977, Yacht Fahrbericht Great Dane 28 Mark III 8,50-m-Langkieler aus Glasharz von Herbert Pielbaum (in german)
- Palstek, Heft 5/2001, S. 54f., Die GFK-Klassiker: Great Dane 28 von Detlef Jens (in german)
- BÅDNYT, November 2005, pp 50-53, Brugtbåd: Great Dane 28, Robust og havgående familie-klassiker von Henrik Hansen (in danish)
- A german daily put the GD 28 on par with e.g. the "Nicholson 32" or Olle Enderlein's "OE 32" in an article about the finest classic GRP-yachts: Die Welt (Deutschland), Sonnabend, 12.03.2005, Klassisch schön. Der Weg zu einer eigenen Yacht führt oft über Oldtimer, die selbst nach 30 Jahren und auch in GFK-Bauweise ihren Wert behalten - wir nennen die Besten von Detlef Jens


text:
This most requested feature of blogger exactly does what MobilePress of WordPress does; phonify or make your website mobile-friendly. Millions of users are accessing the internet via phone every day, thus it does make sense to provide your on-the-go visitors an option to view your webpage in mobile mode (and another option to switch back to desktop/normal view).
This is another Blogger functionality that desperate Blogger users all over the globe are looking for. This mobile view version of Blogger is the answer of Google who must have been pressured by requests of many blogspot owners. And good thing is, you don't have to make necessary adjustments with your HTML codes as the process is just as easy as ticking the radio button and saving it! Here's how you can phonify, make your blogger, blogspot site mobile friendly:
Widget, Plugin To Make Blogger Site Mobile Friendly - The MobilePress version for Blogger (No Coding Needed)
1. Login to Blogger in Draft.
2. Go to your Dashboard -> Settings -> Email and Mobile.
3. Choose "Yes, On Mobile Devices, show the mobile version of my template."
4. Save.
Setting up Blogger mobile web template is really that easy!


text:
155 Poor rural children spent the morning flipping tyres, exercising and completing Fear Factor challenges at Melkbosstrand High School.
Local Strongwoman Liesl Schoonraad, karate instructor Carol Daniels and Constable Debbie Alard oversaw the activities which are set to continue for the rest of the week.
But at the outset the children from Wolwerivier, Melkbosch Village, Vaatjie, Varkplaas and Blouberg Farm looked wary. One little girl had to be coaxed onto the sports field as she complained, "I'm tired!" And then her talk dried up. She refused to answer the question, "What is your dream in life?" and clung to her friends.
Justin 'Bieber'
A group of teenage boys sitting nearby were happy to answer that question. They all want to be soccer and rugby players. One of the boys, Justin, proved his mettle. He flipped a tyre that possibly weighs about 80 kg fifty times as Liesl Schoonraad urged him on with cries of "Do it!" and his peer group shouted "Justin Bieber! Bieber!"
Then 17-year-Old Leonie from Wolwerivier flipped a tyre 20 times. "Do it for the farm, do it for Wolwerivier, do it for the wolwe," her friends chanted. After she completed her challenge Liesl confronted the girl.
"You walked away.
You said you couldn't do it.
And how many did you do?"
Leonie: "Fifteen."
"No, you did twenty!
You know what. You lied to yourself.
How many times in life have you told yourself that you can't do something?
Go get yourself some water."
And so a beaming Leonie walked off to the table with refreshments manned by the head of the Melkbosstrand Community Center, Karen Dreyer.
The Fear Factor challenges started off with a race. The youngsters had to draw green cooldrink up a straw, and with the straw held at an angle in their mouth, run to someone holding a cup some distance away, and then spit the cooldrink into the waiting cup.
An observer speculated, "Hulle sit ore aan vir die grootmense. They've got the water in their mouths!" Finally it was the grown-ups' turn to trick the youngsters with the Tactile Fear Factor challenge. Yucky items inside boxes had to be identified by touch.
A nose
A group of boys congregated around one of the boxes. "It's moving!" one complained before moving nimbly away.
Another one smelt his fingers but that did not help.
"I don't know what it is," he admitted.
Finally the object was uncovered.
"It's a nose!" the boys cried in disgust as a realistic looking but wobbly nose lay exposed before them on a piece of white cloth.
"It's a NOSE!" the cry went up. Of course it wasn't a real nose. But sometimes being an adult gives one an unfair advantage. Tomorrow's activities include Boeresport, rugby and soccer. See you there!
The week-long activities are presented by the Melkbosstrand Police, Melkbosstrand Community Center, the Melkbosstrand Fire Department, ACVV Koeberg, NSRI, Melkbos Neighbourhood Watch, Community Police Forum and individuals presenting workshops.


text:
At UHH Japan Quake and Tsunami Anniversary Fundraiser
One year later the ripples and emotional aftershocks of Japan's tragic event continue to resonate with people worldwide.
The Aloha State continues to show their vibrantly warm spirit by remembering those that lost lives, loved ones and their livelihoods with anniversary fundraisers.
Saturday, March 10, at 3 p.m. the Japan Club at Hawai'i Community College invites everyone to help raise money for Japan's children and youth who need physical and emotional assistance.
Goods donated by local businesses and artists will be up for grabs in the silent auction. People can peruse some of the auction items from Mayumi Oda, Sig Zane, Burgado's Fine Woods and Dragon Mama, while munching on locally favorite foods from Miyo's, Island Naturals, Two Ladies Kitchen and KTA.
In addition to satisfying taste buds, event-goers will enjoy free entertainment provided by Mark Yamanaka, Shizuno Nasu, Yumi Kikuchi and Pele Defense Fund-Native Hawaiian Rights. All proceeds of this event will go to various foundations to help Japanese children and youth.
This fundraiser will take place at the University of Hawai'i at Hilo's Campus Center Plaza and is free to the public. The night will end around 8 p.m. The UHH is located at 200 West Kawili Street in Hilo.


text:
This post contains affiliate links.
BOOK REVIEW: First, Break All The Rules
by Gallup Press (Marcus Buckingham & Curt Coffman)
ABOUT THE BOOK (from Amazon):
Gallup presents the remarkable findings of its revolutionary study of more than 80,000 managers in First, Break All the Rules [affiliate link], revealing what the world's greatest managers do differently. With vital performance and career lessons and ideas for how to apply them, it is a must-read for managers at every level.
Included with this re-release of First, Break All the Rules: updated meta-analytic research and access to the Clifton StrengthsFinder assessment, which reveals people's top themes of talent, and to Gallup's Q12 employee engagement survey, the most effective measure of employee engagement and its impact on business outcomes.
What separates the greatest managers from all the rest?
They actually have vastly different styles and backgrounds. Yet despite their differences, great managers share one common trait: They don't hesitate to break virtually every rule held sacred by conventional wisdom. They don't believe that, with enough training, a person can achieve anything he sets his mind to. They don't try to help people overcome their weaknesses. And, yes, they even play favorites.
In this longtime management bestseller, Gallup presents the remarkable findings of its massive in-depth study of great managers. Some were in leadership positions. Others were front-line supervisors. Some were in Fortune 500 companies; others were key players in small, entrepreneurial firms. Whatever their circumstances, the managers who ultimately became the focus of Gallup's research were those who excelled at turning each individual employee's talent into high performance.
Gallup has found that the front-line manager is the key to attracting and retaining talented employees. This book explains how the best managers select an employee for talent rather than for skills or experience, set expectations, build on each person's unique strengths rather than trying to fix his or her weaknesses, and get the best performance out of their teams.
And perhaps most important, Gallup's research produced the 12 simple statements that distinguish the strongest departments of a company from all the rest. First, Break All the Rules is the first book to present this essential measuring stick and to prove the link between employee opinions and productivity, profit, customer satisfaction and the rate of turnover.
First, Break All the Rules presents vital performance and career lessons for managers at every level — and best of all, shows you how to apply them to your own situation.
First, Break All the Rules is an extremely valuable resource for managers.
The Gallup Organization interviewed 80,000 managers from 400 different companies. The results of their study are compiled into this quick read for managers which includes:
12 questions that management can use to measure the strength of the workplace:
- Do I know what is expected of me at work?
- Do I have the materials and equipment I need to do my work right?
- At work, do I have the opportunity to do what I do best every day?
- In the last seven days, have I received recognition or praise for doing good work?
- Does my supervisor, or someone at work, seem to care about me as a person?
- Is there someone at work who encourages my development?
- At work, do my opinions seem to count?
- Does the mission/purpose of my company make me feel my job is important?
- Are my co-workers committed to doing quality work?
- Do I have a best friend at work?
- In the last six months, has someone at work talked to me about my progress?
- This last year, have I had opportunities at work to learn and grow?
…as well as the Four Keys of Management (each of which is covered in-depth in its own chapter):
- select for talent
- define the right outcomes
- focus on strengths
- find the right fit
This book was eye-opening for me when it comes to the word "talent," which seems to be a buzz word these days. More and more companies are saying they don't care about education or experience because they hire for talent. But what does that really mean?
Gallup breaks down the different types of talent: striving, thinking and relating, and includes an Appendix with lists and descriptions of the most common talents under each of these areas. The writers help managers understand the importance of identifying which talents are necessary for their roles and how selecting for those specific talents leads to the success of the employee as well as the company.
First, Break All the Rules is a must-read for managers. I highly recommend it.


text:
Ice cream headache, also called mind freeze, is a quick-time headache related to extra and rapid intake of ice cream, cold drinks, or other cold dishes. This trouble generally occurs in a hot climate, when a man or woman consumes bloodless stuff very speedily to relieve the frame from excess warmness and humidity.
Due to the consumption of icy stuff, the sinuses' capillaries narrow down, resulting in vasoconstriction. This rapid exchange creates strain close to the touchy nerves and outcomes in pain.
It occurs because of the rapid constriction of the blood vessels inside the palate. Excess cold meals touch the palate, constricting the blood vessels and bringing about a cold stimulus or trigeminal headache. According to a take a look at, it can show up because of some other cold stimulation too.
According to an investigation published in the FASEB Journal in 2012, ice cream headache occurs due to an unexpected boom in blood gliding through the brain's anterior cerebral artery.
The best way to deal with this headache is to drink various heat water. You may also push the tongue to the roof of the mouth, which allows launching the ache. Experts feel that masking the mouth and nose with the hands and respiration hastily helps in instant remedy, increasing the flow of warm air to the palate.
Think of a coffee cafe to relax with pals, and the primary call that vegetation up is Cafe Coffee Day. The concept itself says plenty approximately the brand's vision and the thoughts behind it- VG Siddhartha. The 58-yr-antique entrepreneur discovered dead Wednesday morning took away a generation with him that remodeled the way India checked out espresso. His body of work and numbers speak about the impact he made in the F&B industry of us of a. Have a study some thrilling statistics approximately his journey in the enterprise.
Siddhartha started his adventure as a management trainee with JM Financial Limited in 1983-1984. After operating there for two years, he returned to Bangalore and invested in a stock marketplace card for Rs 30,000 at the side of an organization called Sivan Securities. Interestingly, using 1985, he owned 10,000 acres of coffee farms.
Reportedly, the organization turned into jogging in a big loss, and Siddhartha had bought the 20.32% stake held using him and two CCD affiliate corporations in software program company Mindtree Ltd to Larsen and Toubro Ltd (L&T). The deal helped him repay his debt of about Rs 2,900 crore and hugely advanced his economic condition. As in step with the media report, Cafe Coffee Day has 1,752 shops across India as of March 2019. The enterprise clocked sales of Rs 1,777 crore and Rs 1,814 crore in FY18-19, respectively.
His latest letter addressed to the Board of Directors and workforce discovered how emotional he was. In the letter, he noted, "I fought for a long term, but nowadays I gave up as I could not take any more strain from one of the non-public fairness partners forcing me to buy returned shares, a transaction I had partially completed six months ago borrowing a huge amount of cash from a pal." In addition, he introduced,
"My purpose became by no means to cheat or misinform all of us; I have failed as an entrepreneur. This is my honest submission; I hope you may recognize, forgive, and pardon me sooner or later."
VG Siddhartha loved maintaining a shallow profile in the social circuit, and that's the cause many humans are no longer aware that he was the son-in-regulation of former External Affairs Minister and Karnataka Chief Minister SM Krishna. With more than 30,000 employees, Siddhartha owns the single largest coffee estate that manages the coffee bean supply chain in all his shops. The property stretches over 10,000 acres in Chikamagalur, Karnataka.


text:
tricycle air filter
|item: tricycle air filter
|brand name: Haissky
|place of origin:China
|packing: pp packing with box
|quality: class A
|pruduct num:SSK-THPL00014A1/2/3
|Haissky range of products
|serie name
|accessories name
|engine series
|cylinder kit, head cylinder, cylinder, carburetor, piston set, piston ring set, pump oil, push rod, valve set, rockerarm, cam follower, cam follower with shaft, center clutch, outer clutch, cam shaft, gear speedo, etc.
|transmission series
|shaft kick starter, crank shaft, housing assy, connecting rod kit, sprocket set, clutch assy, clutch friction, chain etc.
|wheel complete
|rear hub, cap rear bub, cap front hub, front hub, sprocket, front brake disk, brake pad, brake shoe, rim, rubber rear hub, collar cushion, racing steering, spoke, bolt sprocket rear, axle, hydraulic brake master cylinder etc.
|cable series
|throttle cable, clutch cable, front brake, meter cable, front switch cable, speed switch, line of battery, wire harness, switch rear brake, speed cable etc.
|body parts
|rear shock absorber, steering stem head assy, gear change pedal, steering stem assy, brake rod, brake pedal, exhaust muffler, foot rest rubber, carrier, side stand, front shock, center stand, seat, fuel tank, handle bar, front mud-guard, front pedal rod, kick starter, rear fork arm, bracket head light, lever set, ignition coil etc.
|electric series
|clutch/brake switch set, battery, fly-wheel assy, clutch/brake lever&switch assy, starter relay, horn, flasher, stator self assy, handle lock, fuel lock, stator assy, starter coil/light coil, C,D,I, rectifier, ignition switch, cap fuel tank etc.
|plastic series
|bulb holder, meter assy, mirror, case of head light, cover fuel tank, lever protector set, house head light, front fender, lens tail light, rear fender, chain cover, head light, tail light, winker light, side cover etc.
|gasket series
|oil seal kit, gasket cylinder, gasket exhaust, full gasket kit, grip rubber set, carburetor joint etc.
|tail box, helmets, sticker, cap, clothes, gloves, paint master, alarm system-mp3, alarm system mp3-2, alarm system, fuel tank net, rear foot pedal with color, rear foot pedal with color inflator, grip rubbe with color, tire sealant, grip rubber with color etc.
|models available
|YBR 125, CG125, GN125, WY125, GS125, XL125, GY125, GY150, NXR125 BROSS, Genesis GXT, BAJAJ PULSAR 180 DTS-1, BAJAJ BOXER CT100/TEC, AX100, C100. BIZ, C90, DT125/175K, RX100, CD100, V80, XL125/X2185, TITAN99, TITAN2000, TITAN150, C100BIZ, CBX2000, NXR125, C100, TS125, DT125, RS100, XLR125 etc.


text:
Frog Earrings - Navy
Frog Earrings - Navy
Sale Sold out
Regular price $ 15.00
Regular priceUnit price per
Sale price
$ 15.00
It's an old story, but a good one: a princess gets a bum deal and is stuck having to marry a frog. She sees past the creature's outside appearance and one kiss later, like the clouds giving way to a beautiful summer day, the frog becomes a prince. We think our frog can do the same for you.
- Enamel Earrings
- Small - Diameter 10MM
- Medium - Diameter 5/8" (approx 15.875MM)
- Polished Backing


text:
A recent video by Cut Video shows a series of parents sitting down to talk their kids about the birds and the bees for the first time. For the most part, the children are shocked by what they are hearing, but young Chase seems to already be well aware where babies come from, and surprises his father with his knowledge. Chase credits his brother Nick with making him so incredibly informed.
Cut Video also released separate videos of each child's individual interview.
"I told you Nick told me a lot of stuff!"
"And then mommy and daddy did a special dance, and there you were."
"… and when you put those things together… the seed is planted."
"She came out of her butt?"
"Yeah do you like have a picture of that?"


text:
Circle JerksAnyone want to explain why Thomas R. Saving, one of Public Trustees of the Social Security and Medicare Trust Fund, whose job is to a) hold the trust funds, b) report to the Congress each year on past and future status, c) report to the Congress immediately if the amount in either trust fund is too small, and d) review policies followed in managing trust funds and recommend changes, is listed as one of the experts for the National Center for Policy Analysis (NCPA), whose stated goal is "to develop and promote private alternatives to government regulation and control, solving problems by relying on the strength of the competitive, entrepreneurial private sector"?
Just asking.
(thanks to taxismom & lapin at dkos for the tip)